Search Results - antoni+ribas

6 Results

Sort By:

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/14/2025 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

PAK4 in Cancer Immune Exclusion

Case 2018-209Researchers at the UCLA David Geffen School of Medicine have proposed that T cell tumor infiltration and the anti-tumor activity of anti-PD-1/PD-L1-based immunotherapy to be modulated through kinase PAK4 activity. BACKGROUNDThe p21-activated kinase 4 (PAK4) is a member of the PAK family of serine/threonine kinases, which are important...

Published: 2/14/2025 | Inventor(s): Antoni Ribas, Catherine Grasso

Keywords(s): Immunotherapy, Life Science Research Tools, Medical Devices and Materials, Oncology, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Medical Devices, Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology

Genetic Mechanisms of Resistance to Anti-PD-1/L1 (UCLA Case No. 2016-075)

Genetic Mechanisms of Resistance to Anti-PD-1/L1SUMMARYUCLA researchers have identified a rare genetic mutation in the interferon receptor signaling pathway that can be used as a diagnostic to predict whether a patient will be or has become resistant to a cancer immunotherapy.BACKGROUNDClinical responses to programmed death‐1 (PD‐1) blockade therapy...

Published: 2/14/2025 | Inventor(s): Antoni Ribas, Daniel Shin, Angel Garcia-Diaz, Blanca Homet Moreno, Jesse Zaretsky

Keywords(s): Immunotherapy, Oncology Immunotherapy, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy

Methods for Predicting Response Patterns to Anti-PD-1 Therapy in Metastatic Melanoma (UCLA Case No. 2016-582)

SUMMARYDr. Roger Lo and colleagues in the Department of Medicine at UCLA have identified a method to predict a melanoma patient’s resistance to pembrolizumab and other immune checkpoint inhibitors.BACKGROUNDImmune checkpoint inhibitors are the most recent stars in cancer therapeutics: the first 4+ drugs in the category have received breakthrough...

Published: 2/14/2025 | Inventor(s): Roger Lo, Antoni Ribas, Willy Hugo, Jesse Zaretsky

Keywords(s):

Category(s): Diagnostic Markers, Therapeutics > Oncology > Oncology Immunotherapy

A Codon-Optimized Lentiviral Vector For Stem Cell Reprogramming (UCLA Case No. 2014-014)

A Codon-Optimized Lentiviral Vector For Stem Cell ReprogrammingSUMMARYUCLA researchers in the Department of Medicine and the Department of Surgery have developed a novel lentiviral vector that expresses a codon-optimized sequence of a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1 as well as a positron emission tomography (PET)...

Published: 2/14/2025 | Inventor(s): Antoni Ribas, Richard Koya, Thinle Chodon

Keywords(s): Drug Delivery, Gene Editing Systems, Gene Therapy, Immunotherapy, iPS/stem cells, Life Science Research Tools, Plasmids / Vectors, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Life Science Research Tools > Plasmids/Vectors, Platforms > Drug Delivery, Therapeutics, Therapeutics > Gene Therapy And Editing, Therapeutics > Immunology And Immunotherapy, Therapeutics > Stem Cells And Regenerative Medicine > Ips Stem Cells

Treatment Of Melanoma With Ferroptosis Inducing Agents

Case 2017-879UCLA researchers in the Departments of Molecular and Medical Pharmacology and Medicine have developed a novel method to treat melanoma.BACKGROUNDImmune checkpoint blockade immunotherapy with anti-PD1 antibody is the preferred treatment for patients with metastatic melanoma that has resisted other therapies. However, there remains a subset...

Published: 2/14/2025 | Inventor(s): Thomas Graeber, Antoni Ribas, Nicolaos Palaskas, Lidia Robert, Jennifer Tsoi

Keywords(s):

Category(s): Therapeutics > Oncology